Inclusion Criteria:  BMI:25-40 kg/m2. HbA1C ≤ 9% on lifestyle therapy with or without monotherapy with metformin or sulphonylureas (SU); or combination therapies (metformin and SU, DPPIV inhibitors, only short acting GLP-1 analogues exenatide (Byeta) and liraglutide (Victoza).  Exclusion Criteria:  Insulin therapy SGLT2 inhibitors Long acting GLP-1 analogues TZDs Medications affecting GI motility (e.g., erythromycin, pramlintide). Medications that may affect glucose metabolism such as corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, and anticoagulants. Unstable diabetic retinopathy, microalbuminuria, macrovascular disease. Upper GI disorder/surgery, debilitating chronic disease, anemia, and symptoms of undiagnosed illnesses. History of alcoholism or substance abuse. Pregnancy or breast feeding, or other comorbidities precluding participation.